Details of the Drug Reposition

General Information of This Drug (ID: DMGAKR9)

Drug Name
AVL-3288   DMGAKR9
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Immune dysregulation DISZV2UF 4A01.2 Phase 1 [1]
Cognitive impairment DISH2ERD 6D71 Phase 1 [2]
Complete androgen insensitivity syndrome DISQL418 LD2A.4 Phase 1 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01851603) Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects. U.S. National Institutes of Health.